Pulmatrix touts Ph1 data for inhaled COPD therapy

Pulmatrix (NSDQ:PULM) touted data today from a dose-ranging Phase I trial of its once-daily inhaled therapy designed for people with chronic obstructive pulmonary disease.
The company’s product is a reformulation of tiotropium bromide, the active component in Boehringer Ingelheim’s blockbuster drug, Spiriva.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix touts Ph1 data for inhaled COPD therapy appeared first on MassDevice.

Source: Mass Device - June 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news